The short version of peptide hormone fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-21. Anything still debated is marked as such rather than presented as settled.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Dopamine β-hydroxylase catalyzes the hydroxylation of not only dopamine but also other phenylethylamine derivatives when available. The minimum requirement seems to be the phenylethylamine skeleton: a benzene ring with a two-carbon side chain that terminates in an amino group.
=== GARS1-related axonal neuropathy (CMT2) === Charcot–Marie–Tooth type 2 (CMT2) is commonly classified as an axonal neuropathy due to the degeneration of nerve axons observed in affected individuals. Unlike CMT type 1, which results from damage to the myelin sheath, CMT type 2 is characterized by direct injury to the axon itself. This axonal damage can disrupt nerve signal transmission between the brain and muscles, resulting in symptoms such as muscle weakness, atrophy, reduced sensation, and foot deformities. The onset of symptoms in CMT2 typically occurs between the ages of 5 and 25. CMT2D is one of more than 31 recognized subtypes of Charcot–Marie–Tooth disease type 2 (CMT2) and is diagnosed when both motor and sensory deficits are present—such as loss of sensation caused by degeneration of sensory axons. In cases where only motor symptoms are observed without sensory involvement, the condition is classified as distal hereditary motor neuropathy type V (dHMN-V). The reason behind the variability in sensory involvement among patients with GARS1-related neuropathy remains unclear. Symptoms of CMT2D typically include muscle weakness, loss of sensation, reduced reflexes, and muscle atrophy, which are similar to those seen in both CMT1 and other CMT2 variants. The severity and combination of symptoms vary widely among patients, particularly regarding the extent of sensory involvement. CMT2D is a result of autosomal dominant mutations in the human GARS1 gene located at 7p14.3 and is thought to be caused by aberrant gain-of-function missense mutations.
When Augustus became sole ruler in 31 BC, he disbanded about half of the over 50 legions then in existence. The remaining 28 legions became the core of the early Imperial army of the Principate (27 BC – AD 284), most lasting over three centuries. Augustus and his immediate successors transformed legions into permanent units, staffed by entirely career soldiers on standard 25-year terms. During the Dominate period (near the end of the Empire, 284–476), legions were also professional, but are little understood due to scarcity of evidence compared to the Principate. What is clear is that late legions were radically different in size, structure, and tactical role from their predecessors, despite several retaining early period names. This was the result of the military reforms of Emperors Diocletian and Constantine I, and of further developments during the 4th century. The legions were identified by Roman numerals, though the spelling sometimes differed from the modern standard. For example, in addition to the spellings "IV", "IX", "XIV", "XVIII" and "XIX", the respective spellings "IIII", "VIIII", "XIIII", "XIIX" and "XVIIII" were commonly used. Legions also bore a cognomen or nickname. Neither a legion's number or cognomen were likely unique enough to identify it, so the combination of the two is usually needed to identify a specific legion. For example, both Legio III Cyrenaica and Legio III Gallica were distinct, long-standing legions of the late Republic and Imperial periods.
Sources: en.wikipedia.org
p3 peptide also known as amyloid β- peptide (Aβ)17–40/42 is the peptide resulting from the α- and γ-secretase cleavage from the amyloid precursor protein (APP). It is known to be the major constituent of diffuse plaques observed in Alzheimer's disease (AD) brains and pre-amyloid plaques in people affected by Down syndrome. However, p3 peptide's role in these diseases is not truly known yet.
The product, α‑ketoadipate, is decarboxylated in the presence of NAD+ and coenzyme A to yield glutaryl-CoA, however the enzyme involved in this is yet to be fully elucidated. Some evidence suggests that the 2-oxoadipate dehydrogenase complex (OADHc), which is structurally homologous to the E1 subunit of the oxoglutarate dehydrogenase complex (OGDHc) (E.C 1.2.4.2), is responsible for the decarboxylation reaction. Finally, glutaryl-CoA is oxidatively decarboxylated to crotonyl-CoA by glutaryl-CoA dehydrogenase (E.C 1.3.8.6), which goes on to be further processed through multiple enzymatic steps to yield acetyl-CoA; an essential carbon metabolite involved in the tricarboxylic acid cycle (TCA).
=== Cancer progression, tumor characterization === The mammographic density is correlated with the collagen density, thus SHG can be used for identifying breast cancer. SHG is usually coupled to other nonlinear techniques such as Coherent anti-Stokes Raman Scattering or Two-photon excitation microscopy, as part of a routine called multiphoton microscopy (or tomography) that provides a non-invasive and rapid in vivo histology of biopsies that may be cancerous.
Sources: en.wikipedia.org
A conservative replacement (also called a conservative mutation or a conservative substitution or a homologous replacement) is an amino acid replacement in a protein that changes a given amino acid to a different amino acid with similar biochemical properties (e.g. charge, hydrophobicity and size). Conversely, a radical replacement, or radical substitution, is an amino acid replacement that exchanges an initial amino acid by a final amino acid with different physicochemical properties.
==== Bands ==== Opus (Austrian band), an Austrian pop-rock group Opus (Yugoslav band), a Yugoslav progressive rock group Opus (Latvian band), Latvian music group Pur (band), a German pop group originally known as "Opus"
The earliest known members of the reptile lineage appeared during the late Carboniferous period, having evolved from advanced reptiliomorph tetrapods which became increasingly adapted to life on dry land. Genetic and fossil data argues that the two largest lineages of reptiles, Archosauromorpha (crocodilians, birds, and kin) and Lepidosauromorpha (lizards, and kin), diverged during the Permian period. In addition to the living reptiles, there are many diverse groups that are now extinct, in some cases due to mass extinction events. In particular, the Cretaceous–Paleogene extinction event wiped out the pterosaurs, plesiosaurs, and all non-avian dinosaurs alongside many species of crocodyliforms and squamates (e.g., mosasaurs). Modern non-bird reptiles inhabit all the continents except Antarctica. Extant reptiles range in size from the tiny Jaragua dwarf gecko (Sphaerodactylus ariasae), which only grow up to 17 mm (0.7 in); to the saltwater crocodile (Crocodylus porosus), which can reach over 6 m (19.7 ft) in length and weigh over 1,000 kg (2,200 lb). As tetrapods, reptiles generally have four limbs or, in the case of snakes and legless lizards, are descended from four-limbed ancestors but have lost the limbs through evolution. Unlike the anamniotic amphibians, reptiles do not rely on waterbodies for reproduction and have no aquatic larval stage. Most reptiles are oviparous with shelled eggs, although several species of squamates are viviparous, as were some extinct marine reptile clades.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.